Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
this off-label use is not backed by the same level of controlled human trial evidence as the lipodystrophy indication Known risks and side effects: Injection site reactions, including erythema, pruritus, pain, and bruising at the injection site Arthralgia (joint pain) and peripheral edema (fluid retention), recognized class effects of GH-axis stimulation Increases in blood glucose and reduced insulin sensitivity, with clinical trials showing a higher rate of elevated HbA1c and new-onset hyperglycemia versus placebo Formation of anti-tesamorelin antibodies, reported in a substantial proportion of treated patients, with unclear long-term clinical significance Contraindicated in people with active malignancy, pituitary or hypothalamic disruption, or pregnancy, per FDA labeling Evidence snapshot: The strongest evidence is a set of Phase 3 human randomized controlled trials that supported FDA approval of tesamorelin for reducing visceral abdominal fat in HIV-associated lipodystrophy (approved 2010), plus a separate placebo-controlled human RCT (Baker et al., 2012, Archives of Neurology) showing improved executive function in older adults
Possible concerns with peptide use may include: Injection site irritation Headache Dizziness Nausea Fatigue Unexpected sleep changes Allergic or immune reactions Contamination risk from poor sourcing Incorrect dosing Medication interactions Unknown long-term safety risks Safety concerns can also depend on the route of administration, dose, product quality, and patient health history
However, avoid taking it simultaneously with iron supplements, as antioxidants may interfere with iron absorption
The two incidents of transaminitis were temporary and the liver function tests returned to normal within a few weeks
& Margolina, A
But the practice has reached a critical moment
